Nevertheless, a few studies investigated into the impact of mutational status for patients with non-small cell lung carcinoma (NSCLC) having irradiation of existing brain metastases, and they mostly reported the negative impact of KRAS mutation on local, intracranial and overall relapse [23, 24]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.